SCHEMBL2154401

SCHEMBL2154401

CC(C)(C)c1ccccc1C(=O)Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.48
ALOX15 P16050 2/20 0.48
TDP1 Q9NUW8 2/20 0.46
TSHR P16473 1/20 0.46
CA2 P00918 1/20 0.43
ATM Q13315 1/20 0.39
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38
RBP4 P02753 1/20 0.38
GAA P10253 2/20 0.37
LMNA P02545 1/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
ELANE P08246 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALOX5 P09917 1/20 0.36
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9712354 0.88 ALDH1A1 (0.42) ALDH1A1ALOX15TDP1TSHRCA2
SCHEMBL9657789 0.87 ALDH1A1 (0.48) ALDH1A1ALOX15TDP1TSHRCA2
SCHEMBL4111692 0.83 ALDH1A1 (0.50) ALDH1A1ALOX15TDP1TSHRGAA
SCHEMBL28009175 0.83 ALDH1A1 (0.43) ALDH1A1ALOX15TDP1TSHRCA2
SCHEMBL1148444 0.82 ALDH1A1 (0.50) ALDH1A1ALOX15TDP1TSHRCA2
SCHEMBL8055375 0.82 CA2 (0.43) ALDH1A1ALOX15TDP1TSHRCA2
SCHEMBL30706305 0.82 CA2 (0.43) ALDH1A1ALOX15TDP1TSHRCA2
SCHEMBL18131351 0.80 ALDH1A1 (0.47) ALDH1A1ALOX15TDP1TSHRCA2
SCHEMBL6949321 0.80 ALDH1A1 (0.50) ALDH1A1ALOX15TSHRCA2GAA
SCHEMBL39249 0.80 ALDH1A1 (0.56) ALDH1A1ALOX15TDP1TSHRCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3162819-B1 IMPROVED ZIEGLER-NATTA CATALYST SYNTHESIS AND PROCESS THEREOF INDIAN OIL CORP LTD (IN) 2018-09-05 EP claimed
US-9896523-B2 Ziegler-Natta catalyst synthesis and process thereof INDIAN OIL CORPORATION LIMITED (IN) 2018-02-20 US claimed
EP-3206695-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B The Board of Trustees of the University of Illionis (US) 2017-08-23 EP claimed
EP-3162819-A1 IMPROVED ZIEGLER-NATTA CATALYST SYNTHESIS AND PROCESS THEREOF Indian Oil Corporation Limited (IN) 2017-05-03 EP claimed
US-20160376384-A1 ZIEGLER-NATTA CATALYST SYNTHESIS AND PROCESS THEREOF INDIAN OIL CORPORATION LIMITED (IN) 2016-12-29 US claimed
CN-104177388-B A kind of bridging bisamide base ytterbium and its preparation method and application 苏州大学 2016-08-17 CN claimed
WO-2016061437-A1 SCALABLE SYNTHESIS OF REDUCED TOXICITY DERIVATIVE OF AMPHOTERICIN B THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-04-21 WO claimed
CN-104211927-A Novel conductive photosensitive polymer NANO & ADVANCED MATERIALS INST LTD 2014-12-17 CN claimed
WO-2014059436-A1 ELECTRONIC TUNING OF SITE SELECTIVITY THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-04-17 WO claimed
US-20100206760-A1 ADHESIVE ARTICLE BASF SE (DE) 2010-08-19 US claimed
US-20090110856-A1 ADHESIVE ARTICLE BASF SE (DE) 2009-04-30 US claimed
WO-2009043907-A1 AN ADHESIVE ARTICLE BASF SE (DE) 2009-04-09 WO claimed
EP-4622465-A1 HYGIENIC TREATMENT OF SURFACES WITH COMPOSITIONS COMPRISING HYDROPHOBICALLY MODIFIED ALPHA-GLUCAN DERIVATIVE Nutrition & Biosciences USA 4, Inc. (US) 2025-10-01 EP disclosed
US-12195432-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2025-01-14 US disclosed
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST NIPPON CHEMIPHAR CO., LTD (JP) 2024-12-19 US disclosed
US-12116351-B2 P2X4 receptor antagonist NIPPON CHEMIPHAR CO., LTD (JP) 2024-10-15 US disclosed
US-4205016-A Multifunctional lithium containing initiator THE DOW CHEMICAL COMPANY (US) 1980-05-27 US disclosed
US-4201729-A CONTAINING BUTADIENE AND/OR ISOPRENE UNITS THE DOW CHEMICAL COMPANY (US) 1980-05-06 US disclosed
US-4200718-A Multifunctional lithium containing initiator THE DOW CHEMICAL COMPANY (US) 1980-04-29 US disclosed
US-3954754-A ANTIHYPERTENSIVES SANDOZ LTD. (CH) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240417379-A1 P2X4 RECEPTOR ANTAGONIST P2RX7, P2RX1, P2RX2 ALDH1A1 3045/4885ALOX15 2387/4885TDP1 3916/4885
US-12116351-B2 P2X4 receptor antagonist P2RX7, P2RX1, P2RX2 ALDH1A1 3019/4885ALOX15 1857/4885TDP1 4154/4885
US-12195432-B2 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases PPARG, PPARA, PPARD ALDH1A1 1659/4885ALOX15 901/4885TDP1 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.